- Orimed Pharma, an affiliate of the JAMP Pharma Group, has expanded its PrLuxa-D portfolio in Canada with the launch of new vitamin D strengths, including 5,000 IU, 10,000 IU, 25,000 IU, and 50,000 IU formulations.
- The expanded portfolio is designed to offer healthcare professionals and patients greater flexibility in vitamin D supplementation and deficiency management across different treatment and prevention needs. Vitamin D supplementation remains widely used to support bone health and maintain adequate vitamin D levels, particularly when sunlight exposure is limited.
- Orimed Pharma said the new formulations align with its focus on innovative bone health therapies and improving access to treatment options tailored to patient needs. The company added that the portfolio expansion reflects its broader commitment to delivering more personalized and accessible healthcare solutions for Canadians.
- The 5,000 IU, 10,000 IU, and 25,000 IU strengths are now available across Canada, while the 50,000 IU formulation is expected to launch on June 15, 2026.
Takeaways
Orimed’s expanded PrLuxa‑D line should make vitamin D supplementation more flexible in Canada by covering a much wider dose range, which helps physicians match treatment to deficiency severity instead of forcing one-size-fits-all dosing. The biggest market effect is better positioning in bone-health and deficiency management, especially for patients who need higher strengths or more precise titration.
Because the new 5,000 IU, 10,000 IU, and 25,000 IU strengths are already available and the 50,000 IU version is coming on June 15, 2026, Orimed is also broadening its footprint in endocrinology and primary care while reinforcing JAMP’s strategy around accessible, practical therapies for Canadians.
Source: CA Newswire
